Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

3(33.3%)

Phase 3

1(11.1%)

9Total

Phase 1(5)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04058470Phase 1Unknown

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Role: lead

NCT03820596Phase 1Completed

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Role: lead

NCT04246359Phase 2Unknown

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Role: lead

NCT04514393Phase 2Unknown

Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma

Role: lead

NCT05021770Phase 1Unknown

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Role: lead

NCT04796857Phase 1Unknown

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Role: lead

NCT02085655Phase 3Unknown

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Role: lead

NCT04476459Phase 1Unknown

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Role: lead

NCT02878278Phase 2Unknown

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Role: lead

All 9 trials loaded